Replimune Group, Inc. is a clinical-stage biotechnology company focused on the development of oncolytic immunotherapies to treat cancer. The company's lead product candidate, RP1, is a selectively replicating version of herpes simplex virus 1 (HSV-1) that is designed to infect and destroy cancer cells. RP1 is currently being evaluated in multiple clinical trials for the treatment of various solid tumors. Replimune is also developing a pipeline of other oncolytic immunotherapies, including RP2, RP3, and RP-Abl, which are designed to target different types of cancer. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.